Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma

Journal of Clinical Oncology

Volumn 26, Issue 28, 2008, Pages 4544-4550

  Haller, Daniel G ^a   Rothenberg, Mace L ^a   Wong, Alfred O ^a   Koralewski, Piotr M ^a   Miller Jr , Wilson H ^a   Bodoky, Gyorgy ^a   Habboubi, Nassir ^a   Garay, Carlos ^a   Olivatto, Luis O ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CLINICAL TRIAL; COLORECTAL CARCINOMA; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DYSESTHESIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HAZARD RATIO; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PARESTHESIA; PHASE 3 CLINICAL TRIAL; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SENSORY DYSFUNCTION; SENSORY NEUROPATHY; SEPSIS; SYMPTOM; TIME; TREATMENT FAILURE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PAIN MEASUREMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 53749092781     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.1249     Document Type: Article

References (22)

1. Simmonds PC: Palliative chemotherapy for advanced colorectal cancer: Systematic review and meta-analysis - Colorectal Cancer Collaborative Group. BMJ 321:531-535, 2000
2. Cunningham D, Pyrhönen S, James R, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413-1418, 1998
3. Rougier P, Van Cutsem E, Bajetta E, et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-1412, 1998
4. Machover D, Diaz-Rubio E, de Gramont A, et al: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7:95-98, 1996
5. Rothenberg ML, Oza AM, Bigelow RH, et al: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 21:2059-2069, 2003
6. Bissery MC, Vrignaud P, Lavelle F, et al: In vivo evaluation of the irinotecan-oxaliplatin combination. Eur J Cancer 33:S177, 1997 (suppl 8; abstr A793)
7. Faivre S, Raymond E, Rixe O, et al: In vitro and in vivo rationale for oxaliplatin in combination with other antitumor agents. Ann Oncol 9:145, 1998 (suppl 2; abstr A554)
8. Guichard SM, Arnould S, Hennebelle I, et al: Combination of oxaliplatin and irinotecan in human colon cancer cell lines in vitro and in vivo. Proc Am Ass Cancer Res 41, 2000 (abstr 1692)
9. Zeghari-Squalli N, Raymond E, Cvitkovic E, et al: Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivate oxaliplatin. Clin Cancer Res 5:1189-1196, 1999
10. Bécouarn Y, Gamelin E, Coudert B, et al: Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients. J Clin Oncol 19:4195-4201, 2001
11. Bajetta E, Beretta E, Di Bartolomeo M, et al: Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients. Oncology 66:132-137, 2004
12. Goldwasser F, Gross-Goupil M, Tigaud J-M, et al: Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: A phase I study in advanced gastrointestinal cancer patients. Ann Oncol 11:1463-1470, 2000
13. Kemeny N, Tong W, Gonen M, et al: Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. Ann Oncol 13:1490-1496, 2002
14. Rougier P, Lepille D, Bennouna J, et al: Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: A randomised, multicentre phase II study. Ann Oncol 13:1558-1567, 2002
15. Scheithauer W, Kornek G, Raderer M, et al: Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. J Clin Oncol 17:902-906, 1999
16. Timotheadou E, Papakostas P, Tsavdaridis D, et al: Irinotecan and oxaliplatin combination, as secondline treatment, in fluoropyrimidine-pretreated advanced colorectal cancer: A phase II study by the Hellenic Cooperative Oncology Group (HeCOG). Tumori 91:309-313, 2005
17. Therasse P, Arbuck S, Eisenhauer E, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
18. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
19. Storniolo AM, Enas NH, Brown CA, et al: An investigational new drug treatment program for patients with gemcitabine. Cancer 85:1261-1268, 1999
20. Tournigand C, Andre T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004
21. Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracilleucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209-1214, 2004
22. Giantonio B, Catalano PJ, Meropol NJ, et al: High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 23:1s, 2005 (suppl; abstr 2)